SEARCH

SEARCH BY CITATION

References

  • 1
    Bertz RJ & Grannemann GRUse of in vitro data and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions.Clin Pharmacokinet1997; 32: 210 258
  • 2
    Coleman T, Ellis SW, Martin IJ, Lennard MS, Tucker GT1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is N-demethylated by cytochromes P450 2D6, 1A2 and 3A4—implications for susceptibility to Parkinson’s disease. J Pharmacol Exp Ther1996; 277: 685 690
  • 3
    Gooderham NJ, Murray S, Lynch AM,et al. Heterocyclic amines: evaluation of their role in diet associated human cancer.Br J Clin Pharmacol1996; 42: 91 98
  • 4
    Catteau A, Bechtel YC, Poisson N, Bechtel PR, Bonaiti-Pellie CA population and family study of CYP1A2 using caffeine urinary metabolites.Eur J Clin Pharmacol1995; 47: 423 430
  • 5
    Kalow W & Tang BKUse of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities.Clin Pharmacol Ther1991; 50: 508 519
  • 6
    Fuhr U & Rost KLSimple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva.Pharmacogenetics1994; 4: 109 116
  • 7
    Eaton DL, Gallagher EP, Bammler TK, Kunze KLRole of cytochrome P4501A2 in chemical carcinogenesis: implications for human variability in expression and enzyme activity.Pharmacogenetics1995; 5: 259 274
  • 8
    Rost KL, Brösicke H, Brockmöller J, Scheffler M, Helge H, Roots IIncrease of cytochrome P450IA2 activity by omeprazole: evidence by the 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin.Clin Pharmacol Ther1992; 52: 170 180
  • 9
    MacLeod S, Sinha R, Kadlubar FF, Lang NPPolymorphisms of CYP1A1 and GSTM1 influence the in vivo function of CYP1A2.Mutat Res1997; 376: 135 142
  • 10
    Nakajima M, Yokoi T, Mizutani M, Shin S, Kadlubar FF, Kamataki TPhenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: absence of mutation prescribing the phenotype in the CYP1A2 gene.Cancer Epidemiol Biomarkers Prev1994; 3: 413 421
  • 11
    Yokoi T, Sawada M, Kamataki TPolymorphic drug metabolism: studies with recombinant Chinese hamster cells and analyses in human populations.Pharmacogenetics1995; 5: S65–S69
  • 12
    MacLeod SL, Tang Y-M, Yokoi Yokoi,et al. The role of recently discovered genetic polymorphism in the regulation of the human CYP1A2 gene.Proceedings of the American Association for Cancer Research1998; 39: 396
  • 13
    Grant DM, Tang BK, Kalow WA simple test for acetylator phenotype using caffeine.Br J Clin Pharmacol1984; 52: 459 464
  • 14
    Butler MA, Lang NP, Young JF,et al. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites.Pharmacogenetics1992; 2: 116 127
  • 15
    Rostami-Hodjegan A, Nurminen S, Jackson PR, Tucker GTCaffeine urinary metabolite ratios as markers of enzyme activity: a theoretical assessment.Pharmacogenetics1996; 6: 121 149
  • 16
    Sambrook J, Fritsch EF, Maniatis T Molecular cloning: a laboratory manual, 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 1989
  • 17
    Ikeya K, Jaiswal AK, Owens RA, Jones JE, Nebert DW, Kimura SHuman CYP1A2: sequence, gene structure, comparison with the mouse and rat orthologous gene, and differences in liver 1A2 mRNA expression.Mol Endocrinol1989; 3: 1399 1408
  • 18
    Daly AK, Brockmöller J, Broly F,et al. Nomenclature for human CYP2D6 alleles.Pharmacogenetics1996; 6: 193 201